Novartis Phase III study shows investigational compound LBH589 extends progression-free survival in multiple myeloma
Swiss drug major Novartis (NOVN: VX) has announced results of a Phase III trial of the investigational compound LBH589 (panobinostat) showing that it significantly extended progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma.
The PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial compared LBH589, in combination with bortezomib and dexamethasone, to tobortezomib plus dexamethasone alone. LBH589 showed significant clinical benefit bringing it a step closer to becoming the first in its class of anti-cancer agents to be available to patients with multiple myeloma. Multiple myeloma affects approximately one to five in every 100,000 people worldwide each year and the five year survival-rate for patients is about 44%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze